Ocrelizumab
| 證據等級: L5 | 預測適應症: 5 個 |
目錄
Ocrelizumab: From Multiple Sclerosis to HER2 Positive Breast Carcinoma
One-Sentence Summary
Ocrelizumab is an anti-CD20 monoclonal antibody approved for multiple sclerosis, acting by depleting CD20-expressing B cells. The TxGNN model predicts it may be effective for HER2 Positive Breast Carcinoma, but currently 0 clinical trials and 0 relevant publications support this specific link — the evidence pack itself flags the prediction as a likely knowledge-graph embedding artifact rather than a mechanism-driven signal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Multiple Sclerosis (per drug background; formal DrugBank/MOA record is a data gap) |
| Predicted New Indication | HER2 positive breast carcinoma |
| TxGNN Prediction Score | 99.89% |
| Evidence Level | L5 |
| Finland Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available from DrugBank (flagged as a High-severity data gap). Based on known background information, ocrelizumab is an anti-CD20 monoclonal antibody that depletes CD20-positive B cells and is approved for multiple sclerosis, an autoimmune disease driven by aberrant B-cell activity.
HER2-positive breast carcinoma, by contrast, is driven by HER2/neu receptor overexpression fueling proliferative signaling pathways — a mechanism with no established biological link to B-cell depletion. The evidence pack's own repurposing rationale is explicit on this point: it assesses the high TxGNN score as most likely reflecting proximity in the knowledge-graph embedding space rather than any true mechanistic connection.
No supporting mechanistic, preclinical, or clinical rationale bridges CD20-targeted B-cell depletion to HER2-driven tumor biology. This prediction should be treated as a candidate for further model-validation research, not as a pharmacologically grounded hypothesis at this stage.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Safety Considerations
Please refer to the package insert for safety information. Note: TFDA/Fimea package insert warnings and contraindications are currently a Blocking data gap (DG001) and must be resolved before any safety pre-assessment can proceed.
Conclusion and Next Steps
Decision: Hold
Rationale: Across all five TxGNN-predicted indications for this candidate (all breast cancer subtypes — HER2-positive, normal-like, PR-positive, luminal A/B, PR-negative), there is no supporting clinical trial or credible literature evidence. The one literature hit found (19 papers retrieved for "breast tumor luminal A or B") is a false-positive keyword match on the letter "B" (hepatitis B vaccines, HLA-B typing, B-1/B-2 lymphocyte biology) with no actual relevance to breast cancer or ocrelizumab. The evidence pack's own analysis concludes the high prediction scores likely reflect knowledge-graph embedding proximity rather than a real mechanistic signal. Combined with the blocking absence of TFDA/Fimea safety data, this candidate does not currently meet the bar to advance past S0.
To proceed, the following is needed:
- TFDA/Fimea package insert (warnings, contraindications) — currently blocking
- Formal mechanism of action record from DrugBank
- Preclinical/in vitro evidence evaluating any role of CD20+ B cells in HER2-driven or other breast cancer subtypes
- Targeted literature search using breast-cancer-specific and ocrelizumab-specific terms to rule out further keyword-driven false positives across the other four ranked candidates
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.